Related Experiment Video

Updated: Jun 17, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K

Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial

Ian Kunkler1, David Cameron1, Mike Dixon1

  • 1Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK.

Lancet (London, England)
|August 10, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

399

Related Experiment Videos

Last Updated: Jun 17, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

399

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Total Brain Diagnostics: Advancing Precision Brain and Mental Health at the Department of Veterans Affairs.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2026

Individual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database.

Health and social care delivery research·2026

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

The Lancet. Oncology·2026

"We do what needs to be done": caregivers' experiences of healthcare and support for people with multiple long-term conditions in the last year of life.

BMC palliative care·2026

Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT.

Health technology assessment (Winchester, England)·2026

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.

Journal of the National Cancer Institute·2026

8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.

Lancet (London, England)·2026

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Lancet (London, England)·2026

A trembling detour to the diagnosis of encephalitis: a neuroborreliosis case report.

Lancet (London, England)·2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial.

Lancet (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us